In brief: Biodiem; Avexa

By Staff Writers
Tuesday, 11 January, 2005

BioDiem (ASX:BDM) has received a US$1m signing-on payment, the first in a number of milestone payments due under its US$8m licence agreement with Akzo Nobel's Nobilon.

Avexa antibacterial studies confirmed

Maryland-based company ImQuest BioSciences has confirmed the activity of Avexa's (ASX: AVX) antibacterial compounds against vancomycin-resistant enterococci (VRE).

Avexa aims to have a lead compound in proof-of-concept models by the end of 2005.

Related News

Lipid science receives new Australia-led online hub

The Lipid Network launched this month to build links between researchers, clinicians and industry...

Proposed Australian trial eyes up blood testing for Alzheimer's

Utilising networks of GPs across three states, a large-scale study intends on combining digital...

Applications open for $300K pandemic therapeutics fellowships

Applications are now open for the Cumming Global Centre for Pandemic Therapeutics' inaugural...

Content from other channels on our network

Six on the shelf: on-the-go protein, ready-to-cook veggies and more

What can food manufacturers learn from viral food trends?

Lion 'flicks the switch' to electric at Speight's Brewery

NZ Winegrowers calls for a White Wine Emoji

Nutrition claims compliance, fresh produce guide updated

Victoria announces "massive" upgrade to one of its busiest hospitals

NSW IRC decision prompts "mixed emotions" from nurses and midwives

Surgical robot expands its scope of procedures

Neuroscientists propose clinical definition for brain fog in menopause

National Pain Alliance launched to advocate for chronic pain

Community food network closes its soft plastics recycling loop

Real-time monitoring reduces risk at pumping station

Victorian oil refinery fire may impact fuel supply

Leafy greens identified as potential metal mining tools

Smart monitoring helps tram network cut water use by 70%

  • All content Copyright © 2026 Westwick-Farrow Pty Ltd